3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
50
Carcinoma, Non-Small-Cell Lung
26
Squamous Cell Carcinoma of Head and Neck
25
Head and Neck Neoplasms
12
Neoplasm Metastasis
11
Neoplasms
10
Colonic Neoplasms
10
Rectal Neoplasms
9
Pancreatic Neoplasms
9
Lung Neoplasms
9
Mouth Neoplasms
6
Carcinoma, Squamous Cell
6
Carcinoma
6
Laryngeal Neoplasms
5
Hypopharyngeal Neoplasms
5
Oropharyngeal Neoplasms
4
Thyroid Neoplasms
3
Solid Tumors
3
Ovarian Neoplasms
3
Gastrointestinal Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Pancreatic Ductal
3
Breast Neoplasms
3
Sarcoma
2
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Laryngeal Diseases
2
mCRC
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Interventions
Bevacizumab
4
palbociclib
2
ribociclib
1
repotrectinib
1
olaparib
1
encorafenib
1
durvalumab
1
atezolizumab
1
Tretinoin
1
Paclitaxel
1
Oviposition
1
Leucovorin
1
Irinotecan
1
Injections
1
Immunotherapy
1
Imatinib Mesylate
1
Fulvestrant
1
Fluorouracil
1
Drug Therapy
1
Drainage
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Digestive System Neoplasms
×
Cetuximab
×
90 days
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled